Atossa Genetics (NASDAQ:ATOS) Share Price Breaks Below 200-Day Moving Average – Here’s Why

Posted by George Bondi on Sep 30th, 2026

Shares of Atossa Genetics Inc. (NASDAQ:ATOS – Get Free Report) crossed below its two hundred day moving average during trading on Monday. The stock has a two hundred day moving average of $3.62 and traded as low as $1.82. Atossa Genetics shares last traded at $1.96, with a volume of 152,908 shares.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on ATOS shares. Wall Street Zen upgraded Atossa Genetics from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 15th. Rodman & Renshaw began coverage on shares of Atossa Genetics in a research report on Tuesday, July 7th. They set a “buy” rating and a $12.00 target price for the company. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Atossa Genetics in a research note on Tuesday, September 8th. Three investment analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $20.33.

Check Out Our Latest Analysis on ATOS

Atossa Genetics Price Performance

The stock has a market capitalization of $19.62 million, a P/E ratio of -0.64 and a beta of 1.27. The stock has a fifty day moving average price of $2.40 and a 200 day moving average price of $3.60.

Atossa Genetics (NASDAQ:ATOS – Get Free Report) last released its quarterly earnings data on Friday, August 7th. The company reported ($0.95) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.02) by $0.07. Research analysts anticipate that Atossa Genetics Inc. will post -3.95 earnings per share for the current year.

Institutional Investors Weigh In On Atossa Genetics

A hedge fund recently bought a new position in Atossa Genetics stock. State Street Corp acquired a new stake in shares of Atossa Genetics Inc. (NASDAQ:ATOS – Free Report) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 39,761 shares of the company’s stock, valued at approximately $77,000. State Street Corp owned approximately 0.40% of Atossa Genetics at the end of the most recent quarter. 12.74% of the stock is currently owned by institutional investors and hedge funds.

About Atossa Genetics

(Get Free Report)

Atossa Genetics, Inc, now operating as Atossa Therapeutics, Inc (NASDAQ: ATOS), is a clinical-stage biopharmaceutical company focused on developing therapies for breast cancer and other diseases affecting breast tissue. The company’s research is centered on targeted treatments intended to address unmet needs in the prevention and treatment of breast cancer.

Atossa’s principal investigational product is oral endoxifen, a selective estrogen receptor modulator being evaluated in clinical studies involving patients with hormone receptor-positive breast cancer.